Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s Form 10-Q for the quarter ended September 30, 2020, filed November 6, 2020. This does not match the request metadata naming Crescent BioPharma, Inc.; verify the issuer before relying on this summary.
Business context
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. It had no approved products or commercial drug sales. Its lead candidate, uproleselan, was in a global Phase 3 trial for relapsed or refractory AML; other programs included GMI-1359, GMI-1687 and rivipansel.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $1.0 million | $0 | $10.0 million | $0 |
| Research and development expense | $10.7 million | $10.7 million | $33.2 million | $35.6 million |
| General and administrative expense | $4.1 million | $3.4 million | $12.7 million | $10.5 million |
| Operating loss | $13.7 million | $14.1 million | $35.9 million | $46.1 million |
| Net loss | $13.7 million | $13.3 million | $35.5 million | $43.2 million |
| Net loss per share | $0.29 | $0.31 | $0.79 | $1.00 |
Revenue in 2020 came from the Apollomics license: a $9.0 million upfront payment recognized in the first quarter and a $1.0 million milestone recognized in the third quarter. No product-sale revenue or royalties had been recognized. Profit margins are not meaningful for this loss-making clinical-stage business.
Cash and cash equivalents were $142.9 million at September 30, 2020, down from $158.2 million at December 31, 2019. Nine-month operating cash use was $29.6 million; investing cash use was $0.03 million; financing provided $14.3 million, primarily from common-stock sales. Total liabilities were $12.2 million, including $3.0 million of operating lease liabilities. The filing reports no borrowings or off-balance-sheet arrangements.
Changes versus the prior comparable period
- Nine-month net loss narrowed by $7.7 million, while operating loss narrowed by $10.1 million, principally reflecting lower R&D costs and 2020 Apollomics revenue.
- Nine-month R&D expense declined $2.4 million, mainly because manufacturing and formulation costs fell $7.3 million; clinical-development expense rose $4.3 million with increased uproleselan trial activity.
- Nine-month G&A expense rose $2.2 million, reflecting personnel costs and higher legal, consulting and professional expenses, including directors’ and officers’ insurance.
- Interest income fell $2.4 million for the nine-month period as average cash balances and interest rates declined. In Q3, this decline contributed to a higher net loss despite a lower operating loss.
- The company sold 4.14 million shares through its prior at-the-market facility during the first nine months, raising $14.1 million net. Shares outstanding were 47.8 million at September 30, versus 43.5 million at year-end 2019.
Outlook, commentary and risks
- Management expected existing cash to fund operating expenses and capital needs into 2022, subject to assumptions that may prove incorrect. The notes also state funds should be sufficient for at least 12 months from the filing date; both statements should be read with the stated uncertainty around spending and trial timing.
- Management expected continued operating losses and negative operating cash flows, and said additional capital would be needed. A new $100 million ATM sales agreement was established in October 2020; no shares had been sold under it as of the report date. Further equity financing could dilute shareholders.
- COVID-19 slowed site initiation and patient recruitment early in 2020; enrollment had returned to forecast levels, but changing infection rates could again affect enrollment and trial timing. The company cited potential effects on clinical sites, suppliers, operations and access to capital.
- The uproleselan Phase 3 trial was expected to complete enrollment in the second half of 2021, but timing remained uncertain. The filing also describes an NCI-led Phase 2/3 trial in older adults with untreated AML.
- Pfizer terminated its rivipansel license effective April 5, 2020 after its Phase 3 trial failed to meet primary and key secondary endpoints; GlycoMimetics regained the rights. A post-termination agreement provides for a possible $25 million milestone and low-single-digit royalties to Pfizer if specified sales occur.
- Apollomics may owe up to approximately $179 million in additional development and commercial milestones plus tiered royalties, but these are conditional and uncertain. The company recognized the $1 million milestone after Chinese regulatory acceptance of a Phase 3 bridging-study design.
- No material legal proceedings were reported. Management assessed disclosure controls as effective as of September 30, 2020.
Important facts for investors to verify
- Confirm that GlycoMimetics, rather than Crescent BioPharma, is the intended issuer and filing.
- Check subsequent filings for cash runway, cash burn, ATM sales and any additional financing or dilution.
- Track uproleselan Phase 3 enrollment and timing, including COVID-19-related disruption, and progress in the NCI trial.
- Verify clinical and regulatory progress for GMI-1359, GMI-1687 and the company’s next steps for rivipansel.
- Distinguish recognized Apollomics revenue from conditional future milestones, royalties and unrecognized product-supply consideration.